QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.002469v1 33/3/426    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paine, M. F. Articles by Watkins, P. B. Search for Related Content PubMed PubMed Citation Articles by Paine, M. F. Articles by Watkins, P. B.

DO MEN AND WOMEN DIFFER IN PROXIMAL SMALL INTESTINAL CYP3A OR P-GLYCOPROTEIN EXPRESSION?

General Clinical Research Center (M.F.P., S.S.L., P.W.S., P.B.W.), Division of Pharmacotherapy (M.F.P., P.B.W.), Department of Medicine (P.B.W.), and Department of Biostatistics (P.W.S.), University of North Carolina, Chapel Hill, North Carolina; and Center for Drug Evaluation and Research (M.-L.C., S.-M.H.), Food and Drug Administration, Rockville, Maryland

The higher systemic clearance of some CYP3A4 [whether also P-glycoprotein (P-gp)] drug substrates in women versus men is attributed in part to a higher hepatic CYP3A4 content in women. This, combined with the general paucity of reported sex differences in the apparent oral clearance of CYP3A4 substrates, suggested a sex-dependent expression of CYP3A4 in the intestine, but in a pattern opposite to that in the liver. Accordingly, duodenal biopsies obtained from healthy men (n = 46) and women (n = 45) were analyzed, by Western blot, for relative CYP3A4, as well as for CYP3A5 and P-gp, expression levels. Among all subjects, CYP3A4 and P-gp varied 8- and 10-fold, respectively. CYP3A5, which was readily detected in 27% of these predominantly white individuals, varied 7-fold. For all three proteins, a sex difference was not detected (p 0.55). The lack of a difference remained for CYP3A4 and P-gp when the analysis was restricted to white individuals (n = 74) or to individuals with undetectable CYP3A5. Comparing the 21 premenopausal women (all were aged <45 years) with the 43 men aged <45 years, again no sex differences were detected in CYP3A4 and P-gp. Comparing the pre- with postmenopausal women, mean CYP3A4 content was 20% lower in the postmenopausal individuals (p = 0.01). The lack of a sex-dependent difference in proximal intestinal CYP3A4 could account, in part, for the lack of reported sex differences in the oral, relative to systemic, clearance of some CYP3A4 substrates. Ramifications of lower intestinal CYP3A4 content in post- versus premenopausal women require further investigation.

This article has been cited by other articles:

				L. Fan, G.-Y. Tao, G. Wang, Y. Chen, W. Zhang, Y.-J. He, Q. Li, H.-P. Lei, F. Jiang, D.-L. Hu, et al. Effects of Ginkgo biloba Extract Ingestion on the Pharmacokinetics of Talinolol in Healthy Chinese Volunteers Ann. Pharmacother., May 1, 2009; 43(5): 944 - 949. [Abstract] [Full Text] [PDF]

				D. J. Greenblatt and L. L. von Moltke Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs J. Clin. Pharmacol., November 1, 2008; 48(11): 1350 - 1355. [Abstract] [Full Text] [PDF]

				N. Isoherranen, S. R. Ludington, R. C. Givens, J. K. Lamba, S. N. Pusek, E. C. Dees, D. K. Blough, K. Iwanaga, R. L. Hawke, E. G. Schuetz, et al. The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent: An in Vitro-in Vivo Evaluation Drug Metab. Dispos., January 1, 2008; 36(1): 146 - 154. [Abstract] [Full Text] [PDF]

				E. C Bell, W. R Ravis, H. M. Chan, and Y.-J. Lin Lack of Pharmacokinetic Interaction Between St. John's Wort and Prednisone Ann. Pharmacother., November 1, 2007; 41(11): 1819 - 1824. [Abstract] [Full Text] [PDF]

				B. Chandler, M. Detsika, S. H. Khoo, J. Williams, D. J. Back, and A. Owen Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects J. Antimicrob. Chemother., September 1, 2007; 60(3): 685 - 689. [Abstract] [Full Text] [PDF]

				J. R. King, T. N. Kakuda, S. Paul, M. M. Tse, E. P. Acosta, and S. L. Becker Pharmacokinetics of Saquinavir With Atazanavir or Low-Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers J. Clin. Pharmacol., February 1, 2007; 47(2): 201 - 208. [Abstract] [Full Text] [PDF]

				D. J. Waxman and C. O'Connor Growth Hormone Regulation of Sex-Dependent Liver Gene Expression Mol. Endocrinol., November 1, 2006; 20(11): 2613 - 2629. [Abstract] [Full Text] [PDF]

				M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, and D. C. Zeldin THE HUMAN INTESTINAL CYTOCHROME P450 "PIE" Drug Metab. Dispos., May 1, 2006; 34(5): 880 - 886. [Abstract] [Full Text] [PDF]

				D. J. Edwards, D. C. Chugani, H. T. Chugani, J. Chehab, M. Malian, and J. V. Aranda Pharmacokinetics of buspirone in autistic children. J. Clin. Pharmacol., May 1, 2006; 46(5): 508 - 514. [Abstract] [Full Text] [PDF]